🇺🇸 FDA
Patent

US 8334313

Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease

granted A61KA61K31/17A61K31/4166

Quick answer

US patent 8334313 (Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease) held by PTC THERAPEUTICS, INC. expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Dec 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/17, A61K31/4166, A61K31/4172, A61K31/4196